Parathyroid hormone-related protein regulates cell survival pathways via integrin alpha6beta4-mediated activation of phosphatidylinositol 3-kinase/Akt signaling.
Parathyroid hormone-related protein regulates cell survival pathways via integrin alpha6beta4-mediated activation of phosphatidylinositol 3-kinase/Akt signaling.
复制标题
DOI:
10.1158/1541-7786.mcr-08-0568
复制
发表时间:
2009-07
期刊:
影响因子:
--
通讯作者:
Falzon M
中科院分区:
文献类型:
--
作者:
Bhatia V;Mula RV;Weigel NL;Falzon M
Parathyroid hormone-related protein (PTHrP) is expressed by human prostatic tissues and cancer cell lines. PTHrP enhances tumor cell growth and metastasis in vivo and upregulates pro-invasive integrin α6β4 expression in vitro. Hallmarks of malignant tumor cells include resistance to apoptosis and anchorage-independent cell growth. In this study, we used the human prostate cancer cell lines C4-2 and PC-3 as model systems to study the effects of PTHrP on these processes. We report that PTHrP protects these cells from doxorubicin-induced apoptosis and promotes anchorage-independent cell growth via an intracrine pathway. Conversely, autocrine/paracrine PTHrP action increases apoptosis in C4-2 cells and has no effect on apoptosis in PC-3 cells. The intracrine effects of PTHrP on apoptosis are mediated via activation of the phosphatidylinositol 3-kinase (PI3-K)/Akt pathway. PTHrP also affects the phosphorylation state of Akt substrates implicated in apoptosis suppression, including glycogen synthase kinase-3 and Bad. The pro-survival effects of PTHrP are accompanied by increases in the ratio of anti- to pro-apoptosis members of the Bcl-2 family and in levels of c-myc. PTHrP also increases NF-κB activity via a PI3-K-dependent pathway. Integrin α6β4 is known to activate PI3-K. Here we also show that knockdown of integrin α6β4 negates the PTHrP-mediated activation of the PI3-K/Akt pathway. Taken together, these observations provide evidence of a link between PTHrP and the PI3-K/Akt signaling pathway through integrin α6β4, resulting in the activation of survival pathways. Targeting PTHrP production in prostate cancer may thus prove therapeutically beneficial.